0000000000225570

AUTHOR

E. Von Stebut

showing 4 related works from this author

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS se…

2017

Background A validated tool for the dynamic severity assessment of hidradenitis suppurativa (HS) is lacking. The aim of this study was to develop and validate such a novel scoring system. Methods A Delphi voting procedure was conducted among the members of the European Hidradenitis Suppurativa Foundation (EHSF) to achieve consensus towards an initial HS Severity Score System (HS4). Strengths and weaknesses of HS4 were examined by a multicenter prospective study. Multivariate logistic regression, discriminant analysis and receiver operating characteristic curves and examination for correlation (Spearman's rho) and agreement (Cohen's kappa) with existing scores were engaged to recognize the v…

AdultMaleMultivariate statisticsmedicine.medical_specialtyConsensusDermatologyLogistic regressionSeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansHidradenitis suppurativaProspective Studies610 Medicine & healthProspective cohort studyReceiver operating characteristicbusiness.industryOdds ratioDermatology Life Quality Indexmedicine.diseaseHidradenitis SuppurativaSurgery030220 oncology & carcinogenesisQuality of LifeFemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbusinessKappa
researchProduct

Development of oil cysts after subcutaneous injection of interferon-α and interleukin-2

2006

Interleukin 2Pathologymedicine.medical_specialtybusiness.industryAlpha interferonDermatologyInterleukine 2Subcutaneous injectionInterferon αToxicityMedicinebusinessInterferon alfamedicine.drugBritish Journal of Dermatology
researchProduct

Resolving lesions in human cutaneous leishmaniasis predominantly harbour chemokine receptor CXCR3-positive T helper 1/T cytotoxic type 1 cells

2009

Summary Background  Cutaneous leishmaniasis (CL) is an epidemic disease affecting millions of individuals worldwide. Treatment options have several side-effects and a vaccine does not exist at present. Objectives  To translate information about protection against CL from mice to man, we studied the local immune response in CL skin biopsies and correlated these findings with clinical information. Methods  The frequency of inflammatory cells was determined in skin biopsies of 20 patients diagnosed with CL using immunohistochemistry. In addition, the nature of the resulting adaptive immune response was assessed by (double) immunostaining against CD4 and chemokine receptors CXCR3 (T helper 1, T…

Pathologymedicine.medical_specialtyChemokinebiologyDermatologyCXCR3Acquired immune systemNatural killer cellInterleukin 21Immune systemmedicine.anatomical_structureImmunologymedicinebiology.proteinCytotoxic T cellCD8British Journal of Dermatology
researchProduct

Macrophage inflammatory protein-1.

2003

Macrophage inflammatory protein (MIP)-1alpha was identified 15 years ago as the first of now four members of the MIP-1 CC chemokine subfamily. These proteins termed CCL3 (MIP-1alpha), CCL4 (MIP-1beta), CCL9/10 (MIP-1delta), and CCL15 (MIP-1gamma) according to the revised nomenclature for chemokines are produced by many cells, particularly macrophages, dendritic cells, and lymphocytes. MIP-1 proteins, which act via G-protein-coupled cell surface receptors (CCR1, 3, 5), e.g. expressed by lymphocytes and monocytes/macrophages (MPhi), are best known for their chemotactic and proinflammatory effects but can also promote homoeostasis. The encouraging results of preclinical studies in murine model…

Molecular Sequence DataCCL18Cell BiologyBiologyMacrophage Inflammatory ProteinsCCL7BiochemistryCCL20CXCL2ImmunologyAnimalsHumansDiseaseCCL15Amino Acid SequenceCCL13CC chemokine receptorsChemokine CCL4Macrophage inflammatory proteinChemokine CCL3The international journal of biochemistrycell biology
researchProduct